Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| GSK plc American Depositary Shares (Each representing two) | GSK3359609 and KEYTRUDA (pembrolizumab) - (INDUCE-4) | Head and Neck Squamous Cell Carcinoma | Phase 2 | Intravenous | Oncology | |
| GSK plc American Depositary Shares (Each representing two) | Xevudy (sotrovimab/VIR-7831) - (COMET-PEAK) | COVID-19 | Phase 2 | Trial Discontinued | Intravenous | COVID-19 |
| GSK plc American Depositary Shares (Each representing two) | Bepirovirsen (IONIS-HBVRx) | Chronic hepatitis B virus (CHB) | NDA Filing | Data Released | Subcutaneous | Antiviral |
| GSK plc American Depositary Shares (Each representing two) | Zejula (niraparib) and Jemperli (dostarlimab) - (FIRST-ENGOT-OV44) | First line advanced ovarian cancer | Phase 3 | Data Released | Zejula oral Jemperli intravenous | Oncology |
| GSK plc American Depositary Shares (Each representing two) | BLU-5937 - (RELIEF) | Chronic cough | Phase 2a | Data Released | oral | Respiratory |
| GSK plc American Depositary Shares (Each representing two) | Cabenuva (cabotegravir, rilpivirine) - (SOLAR) | HIV-1 | Phase 3 | Intramuscular | Anti-HIV | |
| GSK plc American Depositary Shares (Each representing two) | ZEJULA (Niraparib) and JEMPERLI (dostarlimab) - (MOONSTONE) | Ovarian cancer | Phase 2 | oral intravenous | Oncology | |
| GSK plc American Depositary Shares (Each representing two) | Cabenuva (cabotegravir + rilpivirine) - (LATITUDE) | HIV | Phase 3 | Data Released | Intramuscular | Anti-HIV |
